Abstracts

BIC/FTC/TAF IN FRENCH CHILDREN: FREQUENT VIRAL FAILURE BUT RARE ACQUIRED RESISTANCE

Background: Bictegravir-50mg/Emtricitabine-200mg/Tenofovir alafenamide-25mg (BIC/FTC/TAF) is now approved for use in HIV+ children weighing ≥25 kg. However, published data about its efficacy in the paediatric population are limited to one clinical trial including only subjects with suppressed viremia at baseline, good adherence to treatment and short-term follow-up. This “real-life” study aimed to provide long-term data about…